Tbio RUNX1 Runt-related transcription factor 1

Protein Summary

Description

Forms the heterodimeric complex core-binding factor (CBF) with CBFB. RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters (Probable). Essential for the development of normal hematopoiesis (PubMed:17431401). Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the BLK promoter (PubMed:10207087, PubMed:14970218). Inhibits KAT6B-dependent transcriptional activation (By similarity). Involved in lineage commitment of immature T cell precursors. CBF complexes repress ZBTB7B transcription factor during cytotoxic (CD8+) T cell development. They bind to RUNX-binding sequence within the ZBTB7B locus acting as transcriptional silencer and allowing for cytotoxic T cell differentiation. CBF complexes binding to the transcriptional silencer is essential for recruitment of nuclear protein complexes that catalyze epigenetic modifications to establish epigenetic ZBTB7B silencing (By similarity). Controls the anergy and suppressive function of regulatory T-cells (Treg) by associating with FOXP3. Activates the expression of IL2 and IFNG and down-regulates the expression of TNFRSF18, IL2RA and CTLA4, in conventional T-cells (PubMed:17377532). Positively regulates the expression of RORC in T-helper 17 cells (By similarity). Isoform AML-1G shows higher binding activities for target genes and binds TCR-beta-E2 and RAG-1 target site with threefold higher affinity than other isoforms. It is less effective in the context of neutrophil terminal differentiation. Isoform AML-1L interferes with the transactivation activity of RUNX1. Core binding factor (CBF) is a heterodimeric transcription factor that binds to the core element of many enhancers and promoters. The protein encoded by this gene represents the alpha subunit of CBF and is thought to be involved in the development of normal hematopoiesis. Chromosomal translocations involving this gene are well-documented and have been associated with several types of leukemia. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

Uniprot Accession IDs

• Q01196
• A8MV94
• B2RMS4
• D3DSG1
• O60472
• O60473
• O76047
• O76089
• Q13081
• Q13755
• Q13756
• Q13757
• Q13758
• Q13759
• Q15341
• Q15343
• Q16122
• Q16284
• Q16285
• Q16286
• Q16346
• Q16347
• Q92479

Gene Name

• RUNX1

Ensembl ID

• ENST00000300305
• ENSP00000300305
• ENSG00000159216
• ENST00000344691
• ENSP00000340690
• ENST00000358356
• ENSP00000351123
• ENST00000437180
• ENSP00000409227

Symbol

• AML1
• CBFA2
• AML1
• CBFA2
• EVI-1
• AMLCR1
• PEBP2aB
• CBF2alpha
• AML1-EVI-1
• PEBP2alpha

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
hub protein	0.99
molecular function	0.99
PubMedID	0.98
transcription factor perturbation	0.98
biological process	0.96

Protein Classes

PANTHER Classes

Protein / Transcription Factor / Runt-related Transcription Factor 1

Protein / Nucleic Acid Binding / Runt-related Transcription Factor 1

Protein / ... / Runt Transcription Factor / Runt-related Transcription Factor 1

DTO Classes

Protein / Transcription Factor / Immunoglobulin Fold Transcription Factor / Runt Transcription Factor / Runt-related Transcription Factor 1

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 148.49   (req: < 5)

Gene RIFs: 748   (req: <= 3)

Antibodies: 1012   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 148.49   (req: >= 5)

Gene RIFs: 748   (req: > 3)

Antibodies: 1012   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 37

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0